Lung Graft Dysfunction
Conditions
Brief summary
This is a prospective, monocentric, observational cohort study whose main objective is to describe the number and rate of patients who developed DSAs (Donor Specific Antibody) at 6 months post-surgery with implantation of a cryopreserved lung homograft.
Detailed description
Lung homograft is used in a large number of complex malformations. It is accepted that homografts may induce immune reactions in the recipient, but no immunological studies have been carried out to characterize the recipient's immune reactions to the homograft and their potential impact on valve function. In this project, the authors propose to study the immunizing character of cryopreserved lung homografts by identifying the appearance of antibodies directed against the HLA, DSA (Donor Specific Antibodies) molecules of the graft (lung homograft) at 1 month and 6 months after its surgical implantation.The primary objective will be analyzed by describing the rate of patients who developed DSA at 6 months post-surgery with implantation of a cryopreserved lung homograft.
Interventions
PROCEDUREBlood collection T0
2 blood samples will be taken in addition to the pre-operative check-up.
PROCEDUREBlood collection 6 months
1 blood sample will be taken 6 months after surgery.
Sponsors
Assistance Publique Hopitaux De Marseille
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for control patients: * Patient receiving a cryopreserved pulmonary valve homograft * Patient aged 14 or over * Signature of consent by adult patients/parents/guardians and assent by children Inclusion Criteriafor patients with lung homograft : * Patientsreceiving a cardiac surgery with extracorporeal circulation and without lung homograft
Exclusion criteria
for both group * Emergency surgery patient * Pregnant women or childbirth within the last 6 months * Transfusion during the surgery or within the last 6 months * Patient with DSAs detected before the surgery * Patient with anti-HLA antibodies (non-DSAs) detected before the surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection of DSA at 6 months | 6 months | Luminex® detection of DSA at 6 months after lung homograft implantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DSA Quantification | 6 months | DSA will be quantified in patients who developed DSA 6 months after lung homograft implantation |
| antibody anti-HDLA (non DSA) detection | 6 months | Detection or non-detection of non-DSA anti-HLA antibodies will be assessed by Mean Fluorescence Intensity. |
| Early degeneration of the homograft | 6 months | The early degeneration of the homograft will be defined by the occurrence of at least one of the following criteria: * Need to replace lung homograft * Need for dilatation during catheterization of lung homografts * Maximum gradient across the lung homograft ≥ 30mmhg on echography at 6 months * Pulmonary insufficiency ≥ moderate on echography at 6 months |
Contacts
Primary ContactMarien Lenois, PhD
Backup ContactClement PIERRE, PhD
Outcome results
None listed